Cure My Disease

Don't miss your cure!

 Log in / Sign up

Double CAR t attack shows promise for tough childhood leukemia

NCT ID NCT05674175

Recruiting now Disease control Sponsor: Stephan Grupp MD PhD Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 29 times

Summary

This study tests a new approach for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. Participants receive two different types of their own modified immune cells (CAR T cells) designed to target two proteins on cancer cells: CD19 and CD22. The goal is to see if using both together is safe and works better than one alone, especially for those who have already tried other cell therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

B LINEAGE LYMPHOBLASTIC LYMPHOMA B LINEAGE LYMPHOBLASTIC LYMPHOMA B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA